One Colonoscopy, Thirteen Years, and a Mortality Signal That Didn’t Arrive: What the NordICC Trial Really Breaks
The NordICC RCT cut colorectal cancer incidence but missed its mortality target — exposing a design flaw that should...
FDA Regulatory Policy
The FDA Doesn’t Have a GLP-1 Problem. It Has an Evidence Problem.
A trial emulation study of 174,678 type 1 diabetes patients shows GLP-1RAs cut major cardiovascular events and end-stage kidney...